ASH 2024 | Updated safety and efficacy of BMS-986393 in patients with R/R myeloma and 1-3 prior LOT

GPRC5D is a new target that’s been discovered on myeloma cells and we already have a bispecific antibody, talquetamab, that targets this antigen that is currently approved for patients that have had four or more lines of therapy and it’s something that we use, you know, quite a bit in clinic. That agent does have its unique toxicities, as do most GPRC5D targeting therapies, that includes dysgeusia, weight loss, that can be a challenge for some patients that receive the bispecific antibody. So, you know, the intent of this product, which is a CAR T-cell product, is to use the same target, but deliver a one-time therapy, you know, with this agent. And there have been previous reports of the Phase I study showing benefit in patients that were heavily pre-treated with this agent, showing very high response rates of around 90% and durable responses as well. And we’ll have an update of that cohort at ASH this year. And this is a cohort that is looking at one to three prior lines of therapy. So these patients are a bit earlier in their disease course. And we’ve treated 31 patients at the time of the data cut off in this trial. And so far, the activity looks very good. It looks very comparable to what we see in the heavily pre-treated patient population. You’re seeing very high response rates of, again, around 90%. About around half these patients are achieving these complete responses. And then many of these patients are also achieving MRD negative disease. So our hope is that this will be durable responses that will last, as we’ve seen in the later line cohorts, perhaps it’ll be even better in this earlier line cohort. So no new safety signals were observed in treating these patients early. And so far, the efficacy seems quite good.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.